Matthew Wadas
Optometrist · Herkimer, NYNPI 1821448358
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 69.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $12,256 and has fallen 91.4% since, to $1,056 in 2025. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $68.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Kala Pharmaceuticals, Inc.$865
- Sun Pharmaceutical Industries Inc.$860
- Bausch & Lomb Americas Inc.$828
- Alcon$644
- Tearlab Corp$377
- plus $1K from 14 others
What the payments were for
- Consulting fees$7905%
- Speaking & faculty fees$8,40051%
- Travel & lodging$1,75011%
- Food & beverage$5,67734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $11,589 |
| Kala Pharmaceuticals, Inc. | 5 | $865 |
| Sun Pharmaceutical Industries Inc. | 51 | $860 |
| Bausch & Lomb Americas Inc. | 51 | $828 |
| Alcon | 36 | $644 |
| Tearlab Corp | 2 | $377 |
| Coopervision Inc. | 7 | $267 |
| Tarsus Pharmaceuticals, Inc. | 7 | $224 |
| Novartis | 10 | $187 |
| Oyster Point Pharma, Inc. | 6 | $137 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $125 |
| Optos, Inc. | 2 | $107 |
| Sight Sciences, Inc. | 2 | $85 |
| Johnson & Johnson Vision Care, Inc. | 2 | $52 |
| Dompe US, Inc. | 2 | $48 |
| Harrow Eye, LLC | 2 | $47 |
| Biotissue Holdings Inc. | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$10,353
- EYSUVIS$790
- TearLab Osmolarity System$377
- Rhopressa$125
- Rocklatan$125
- Precision 1$125
- MIEBO$125
How this compares
$16,616 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 58 | $78,773 |
| LumiganBimatoprost | 193 | $78,768 |
| XiidraLifitegrast | 36 | $64,563 |
| Cyclosporine | 70 | $54,559 |
| TyrvayaVarenicline Tartrate | 66 | $43,144 |
| MieboPerfluorohexyloctane/Pf | 26 | $30,521 |
| CequaCyclosporine | 13 | $15,298 |
| Restasis MultidoseCyclosporine | 17 | $12,197 |
| EysuvisLoteprednol Etabonate | 15 | $9,148 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 34 | $8,315 |
| VyzultaLatanoprostene Bunod | 16 | $7,841 |
| Loteprednol Etabonate | 30 | $6,145 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $4,951 |
| Latanoprost | 534 | $4,880 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $3,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose | $11,589 | $169,738268 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $828 | $102,92578 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $137 | $43,14466 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $860 | $15,29813 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $865 | $9,14815 claims |
| AlconSimbrinza | $644 | $8,31534 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $6,14530 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $125 | $4,95112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Herkimer
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.